News
Vir Biotechnology collaborates National Institutes of Health Vaccine Research Center on antibodies against Coronaviruses
Vir and NIAID will work together to identify and optimize combinations of antibodies against coronaviruses, including SARS-CoV-2, SARS and MERS.
Novavax and Serum Institute of India to develop and commercialize Malaria Vaccine Candidate
Novavax and Serum Institute of India signed a commercial license agreement for the use of Novavax’ proprietary Matrix-M vaccine adjuvant with SII’s malaria vaccine candidate.
U.S. FDA accepts Biologics License Application for Mylan and Biocon's proposed biosimilar Bevacizumab for review
Mylan and Biocon's proposed biosimilar Bevacizumab is expected to be the third biosimilar from the partnered portfolio for cancer patients in the U.S.
Zydus gains exclusive rights to develop and commercialize XOMA’s IL-2 antibody
Through this collaboration, Zydus will develop the new IO drug candidate through human proof-of-concept and each company has the potential to receive pre-defined shares of future proceeds.
Exhibit in the 'India Pavilion' at BIO 2026
